(Q52919769)

9 May 2018

title

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. (English)

1 reference

9 May 2018

0 references

1 reference

Martin Kaiser

1

1 reference

9 May 2018

Maren Mieth

2

1 reference

9 May 2018

Peter Liebisch

3

1 reference

9 May 2018

Romy Oberländer

4

1 reference

9 May 2018

Jessica Rademacher

5

1 reference

9 May 2018

Christian Jakob

6

1 reference

9 May 2018

Lorenz Kleeberg

7

1 reference

9 May 2018

Claudia Fleissner

8

1 reference

9 May 2018

Edgar Braendle

9

1 reference

9 May 2018

Malte Peters

10

1 reference

9 May 2018

David Stover

11

1 reference

9 May 2018

Orhan Sezer

12

1 reference

9 May 2018

Ulrike Heider

13

1 reference

9 May 2018

publication date

10 March 2008

1 reference

9 May 2018

European Journal of Haematology

published in

1 reference

9 May 2018

volume

80

1 reference

9 May 2018

issue

6

1 reference

9 May 2018

page(s)

490-494

1 reference

9 May 2018

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Myeloma bone disease and proteasome inhibition therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

RANK ligand and osteoprotegerin in myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Myeloma affects both the growth and function of human osteoblast-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Wnt signaling in osteoblasts and bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Secreted antagonists of the Wnt signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Pathophysiology of multiple myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Role of osteoblast suppression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2008.01065.X

10.1111/J.1600-0609.2008.01065.X

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

18331598

1 reference

9 May 2018